Cardiovascular Pharmacology

Cardiovascular Pharmacology — Expert Level

How it begins

Análisis profundo de los fármacos que actúan sobre el sistema cardiovascular: mecanismos moleculares, farmacocinética, efectos adversos y aplicación clínica en hipertensión, insuficiencia cardíaca, arritmias, cardiopatía isquémica y coagulopatías.

What it covers

1. Cardiovascular Pharmacological Physiology
2. · Determinants of Cardiac Output
3. · Cardiac Action Potential — Target of Antiarrhythmics
4. · The Renin-Angiotensin-Aldosterone System (RAAS) — Central Axis of CV Pharmacology
5. · Adrenergic Receptors — Key to Understanding Sympathomimetics and Beta Blockers
6. Antihypertensives — General Overview
7. · Functional Classification of Antihypertensives
8. · Compelling Indications — The Right Drug for the Right Patient
9. ACEIs and ARA-II — RAAS inhibition
10. · Angiotensin Converting Enzyme Inhibitors (ACEIs)
11. · Angiotensin II Receptor Antagonists (ARA-II / Sartans)
12. Beta Blockers — β-Adrenergic Antagonists
13. · Classification of Beta Blockers
14. · Beta Blockers in Heart Failure — The Paradox Resolved
15. Calcioantagonists — Ca²⁺ Antagonists
16. · The Three Structural Classes with Different Pharmacological Profiles
17. Diuretics — Volume Reduction
18. · Thiazidic and Similar Diuretics — First Line in HTN
19. · Loop Diuretics — Maximum Natriuretic Potency
20. · Potassium-Sparing Diuretics
21. · SGLT-2 Inhibitors — The New Diuretics-Cardioprotectors
22. Antianginal drugs — Treatment of Angina
23. · Organic Nitrates — The Historical Vasodilators
24. · Ivabradine — Bradycardia without Negative Inotrophism
25. · Ranolazine — The Metabolic Antianginal
26. Pharmacology of Heart Failure
27. · The Four Pillars of Disease Modifying Treatment in HFrEF
28. · Digoxin — The Oldest Drug Still in Use
29. · Treatment of Acute Decompensated HF — The Urgency
30. Antiarrhythmics — Vaughan Williams Classification
31. · Amiodarone — The Most Powerful and Most Toxic Antiarrhythmic
32. · Adenosine — The Antiarrhythmic of Choice in Acute SVT
33. Anticoagulants — Inhibition of Coagulation
34. · Heparins — Classic Parenteral Anticoagulants
35. · Warfarin and Oral Anticoagulants Vitamin K-Dependent
36. · Direct Oral Anticoagulants (DOACs / NOACs) — The New Era
37. Antiplatelet Agents
38. · Acetylsalicylic Acid (ASA / Aspirin) — The Classic Antiplatelet
39. · ADP P2Y₁₂ Receptor Inhibitors — Thienopyridines and Analogs
40. · Glycoprotein IIb/IIIa (GP IIb/IIIa) inhibitors
41. Thrombolytics — Plasminogen Activators
42. Hypolipidemics — Atherosclerotic Risk Reduction
43. · Statins (HMG-CoA Reductase Inhibitors) — The Most Important Class
44. · Ezetimibe — Inhibition of Intestinal Cholesterol Absorption
45. · PCSK9 Inhibitors — The Third Hypolipidemic Revolution
46. · Other Relevant Hypolipidemics
47. Vasopressors and Inotropes in Shock